Augmentin ES-600 is a distinct prescription oral suspension containing amoxicillin and clavulanate potassium. After reconstitution, each 5 mL contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid, supplied as clavulanate potassium. Amoxicillin is a penicillin-class antibacterial, while clavulanate inhibits certain bacterial beta-lactamase enzymes. The product's approximately 14:1 amoxicillin-to-clavulanic-acid ratio distinguishes it from standard Augmentin suspensions, which use different concentrations and component proportions. Augmentin ES-600 is not plain amoxicillin liquid and is not simply a larger-strength version of every other amoxicillin/clavulanate product.
The July 2026 U.S. FDA prescribing information identifies Augmentin ES-600 for specified pediatric bacterial infections in children aged 3 months to 12 years weighing 8 kg to 40 kg. Its labeled indications include acute bacterial sinusitis and recurrent or persistent acute otitis media under defined microbiological and clinical conditions. The medicine is not indicated for certain infections involving Streptococcus pneumoniae with higher penicillin minimum inhibitory concentrations. These restrictions matter because the ES-600 brand has its own clinical and regulatory identity rather than sharing every indication of conventional Augmentin products.
For a family with an existing prescription, the central task is to verify the exact ES-600 formulation, complete 600/42.9 mg per 5 mL concentration, approved package, preparation status and pharmacy dispensing instructions. FDA labeling identifies three bottle configurations and requires refrigerated storage after reconstitution, with unused liquid discarded after 10 days. It also explicitly states that ES-600 is not substitutable with other Augmentin or Augmentin XR formulations. This page focuses on the distinct ES-600 product; the standard Augmentin oral suspension guide covers ordinary liquid strengths, while ES-600 vs regular Augmentin provides the dedicated formulation comparison.
Augmentin ES-600 is a branded oral antibacterial product supplied as powder for suspension. It contains two active components: amoxicillin, supplied as amoxicillin trihydrate, and clavulanic acid, supplied as clavulanate potassium. The powder is reconstituted to form an oral liquid with the labeled concentration of 600 mg/42.9 mg per 5 mL. These figures describe the finished liquid, not the total amount of either ingredient in the bottle.
The combination is designed to provide amoxicillin activity alongside inhibition of certain beta-lactamase enzymes by clavulanate. This mechanism can matter when treating infections involving susceptible beta-lactamase-producing bacteria, but it does not eliminate all resistance mechanisms. An Augmentin ES-600 prescription therefore depends on the infection and patient circumstances, not merely on the fact that it contains two active ingredients.
The ES-600 designation is a specific branded formulation identity. It should not be used as a synonym for standard Augmentin 400 mg/57 mg per 5 mL liquid, a conventional tablet or Augmentin XR. These products contain related active ingredients, but their component ratios, labeled populations and substitution rules differ.
The brand name also should not be confused with proof of current commercial supply. A published FDA approval or DailyMed label can identify a regulated product without establishing that a particular pharmacy has a corresponding branded bottle in inventory. A valid prescription and dispensing verification remain necessary.
Readers looking for the complete branded family can consult the Augmentin brand overview. Information about the broader two-ingredient generic medicine belongs in the amoxicillin/clavulanate product guide.
The strength 600 mg/42.9 mg per 5 mL identifies two separate active-component concentrations. In every 5 mL of correctly prepared Augmentin ES-600 suspension, the FDA label specifies 600 mg of amoxicillin and 42.9 mg of clavulanic acid. The clavulanic acid is supplied as its potassium salt. A label that reports only 600 mg amoxicillin does not fully identify the combination product.
Dividing the amoxicillin quantity by the clavulanic-acid quantity gives a ratio of approximately 14:1. This differs from the 4:1 and approximately 7:1 ratios used in standard Augmentin oral suspensions. The difference is a pharmaceutical characteristic, not evidence that ES-600 is universally more effective or suitable for a wider range of infections.
The component ratio helps explain why matching the first number on two different liquid labels does not establish interchangeability. For example, standard 400 mg/57 mg per 5 mL suspension provides a different relationship between amoxicillin and clavulanic acid. ES-600 is also not a concentrated version of plain amoxicillin suspension because the additional clavulanate component changes the medicine's identity.
The complete concentration should appear in pharmacy records and dispensing instructions. It is separate from the bottle's prepared volume: a 75 mL bottle and a 200 mL bottle can contain liquid at the same 600/42.9 mg per 5 mL concentration while supplying different total volumes.
The approximately 14:1 ratio is useful for recognizing ES-600 but should never be used by families to calculate an alternative suspension volume, change a regimen or replace a prescribed product independently.
| Product characteristic | FDA-labeled value | Identification significance |
|---|---|---|
| Amoxicillin | 600 mg per 5 mL after reconstitution | Penicillin-class antibacterial component. |
| Clavulanic acid | 42.9 mg per 5 mL after reconstitution | Beta-lactamase inhibitor component supplied as clavulanate potassium. |
| Component ratio | Approximately 14:1 | Distinguishes ES-600 from standard Augmentin liquid ratios. |
| Dosage form | Powder for oral suspension | Requires correct preparation before use. |
| Product category | Prescription-only branded pediatric combination antibiotic | Not plain amoxicillin or a routine standard-suspension strength. |
The July 2026 FDA consolidated prescribing information identifies Augmentin ES-600 for specific bacterial infections in pediatric patients aged 3 months to 12 years weighing 8 kg to 40 kg. Its labeled uses include acute bacterial sinusitis and recurrent or persistent acute otitis media, each subject to defined organism and susceptibility conditions.
For acute bacterial sinusitis, the FDA describes a role for ES-600 in the specified pediatric population when infections involve designated confirmed or suspected beta-lactamase-producing pathogens and certain Streptococcus pneumoniae isolates with reduced penicillin susceptibility. This is a defined antibacterial indication, not approval for every episode of nasal congestion or suspected sinus infection.
For recurrent or persistent acute otitis media, the label identifies susceptible S. pneumoniae, Haemophilus influenzae and Moraxella catarrhalis under specified conditions. The labeled population includes children with recent antibacterial treatment for acute otitis media and the relevant age or daycare-attendance risk factors. These conditions distinguish the ES-600 indication from a general statement that the product treats any childhood ear infection.
The FDA states that ES-600 is not indicated for the specified sinusitis or recurrent/persistent otitis-media infections caused by S. pneumoniae with penicillin MIC values of 4 mcg/mL or greater. This limitation prevents the product's higher amoxicillin concentration from being interpreted as a guarantee against resistant organisms.
The prescription decision depends on clinical assessment, suspected or documented pathogens, susceptibility information and patient characteristics. The product's labeling should not be converted into a caregiver-directed treatment-selection algorithm or used as justification for self-treatment.
The ES-600 indication framework is narrower than the complete list of infections addressed by other Augmentin formulations. The ES-600 vs regular Augmentin comparison explains the product-specific differences without turning this page into a broad infection-treatment hub.
| FDA-labeled use | Relevant pediatric population | Important boundary |
|---|---|---|
| Acute bacterial sinusitis | Age 3 months to 12 years; weight 8 kg to 40 kg | Limited to specified bacterial pathogens and susceptibility conditions. |
| Recurrent or persistent acute otitis media | Specified pediatric patients within the labeled age and weight range, with relevant risk factors | Not equivalent to routine treatment of every episode of acute otitis media. |
| Specified S. pneumoniae infections with penicillin MIC at least 4 mcg/mL | No ES-600 indication under the stated limitation | Higher amoxicillin concentration does not override the FDA susceptibility restriction. |
The FDA's July 2026 ES-600 labeling specifies children aged 3 months to 12 years weighing 8 kg to 40 kg. The age and weight boundaries are part of the approved product framework and should remain visible when interpreting a pharmacy listing or prescription. They are not a chart for selecting an individual dose.
For children outside the labeled group, the existence of a concentration of 600 mg/42.9 mg per 5 mL does not establish an appropriate indication or regimen. The FDA notes that experience with ES-600 in adults and pediatric patients weighing more than 40 kg is unavailable. Other Augmentin products have their own population requirements and should not be assumed to replace ES-600.
The label contains specific pediatric dosing and administration instructions, including treatment-related conditions, but the actual prescription must be established by a qualified clinician. This product page deliberately avoids weight-to-volume conversion tables and does not recommend a dose for a particular child.
ES-600 is supplied as a liquid, which may be practical for young patients who cannot swallow tablets. However, ease of administration does not determine clinical suitability. The exact formulation still must be checked against the infection, patient history, active-component concentration and professional directions.
Any proposed change between ES-600 and an ordinary Augmentin suspension, chewable tablet or conventional tablet requires prescriber and pharmacist evaluation rather than a calculation based on amoxicillin milligrams. The labeled substitution prohibition remains applicable.
The July 2026 FDA prescribing information and the ES-600 product labeling identify three branded bottle configurations for the 600 mg/42.9 mg per 5 mL powder for oral suspension: 75 mL, 125 mL and 200 mL. These volumes refer to the prepared suspension rather than the amount of dry powder or the volume of water added during reconstitution.
The corresponding labeled National Drug Codes are 81964-003-51 for the 75 mL bottle, 81964-003-69 for the 125 mL bottle and 81964-003-54 for the 200 mL bottle. Each NDC identifies a specific labeled product and package configuration. It does not independently prove current commercial distribution, product authenticity, clinical suitability or real-time pharmacy inventory.
The branded product is described as strawberry cream-flavored powder for oral suspension. A pharmacy or product database may display the same concentration across multiple original bottle sizes. The actual dispensing quantity should therefore be checked separately from both the active-ingredient concentration and the manufacturer's package volume.
Generic or differently labeled products should not automatically be assigned the branded ES-600 NDCs. FDA-approved product identities, application relationships and package listings must be evaluated individually. A nonproprietary amoxicillin/clavulanate listing is not enough to demonstrate equivalence to the branded ES-600 formulation.
The package records below identify labeled presentations, not a catalog of confirmed pharmacy stock. Patients seeking a particular branded package should have the dispensing pharmacy verify the product and quantity associated with the existing prescription.
| Labeled branded product | NDC | Final prepared volume | Product verification note |
|---|---|---|---|
| Augmentin ES-600 powder for oral suspension | 81964-003-51 | 75 mL | Branded package identifier; current supply requires pharmacy confirmation. |
| Augmentin ES-600 powder for oral suspension | 81964-003-69 | 125 mL | Same labeled concentration in a different prepared bottle size. |
| Augmentin ES-600 powder for oral suspension | 81964-003-54 | 200 mL | Larger original package configuration, not a different concentration. |
Augmentin ES-600 is supplied as dry powder that must be properly reconstituted before administration. The FDA's July 2026 prescribing information directs preparation at the time of dispensing. The amount of water used depends on the original bottle size, and it is not equal to the final labeled suspension volume.
FDA Table 5 identifies 70 mL of water for a 75 mL final bottle, 110 mL for a 125 mL final bottle and 180 mL for a 200 mL final bottle. The label instructs the preparer to loosen the powder, add the measured water in two stages and shake thoroughly. These are regulatory preparation specifications for the dispensing process, not instructions for caregivers to improvise mixing.
Correct reconstitution is necessary to obtain the labeled concentration of both active components per 5 mL. Too much or too little water can change the resulting concentration and make a prescribed measured volume inaccurate. The dispensing pharmacist should establish whether the bottle has been prepared and whether the correct product and volume have been supplied.
The final liquid should be accompanied by appropriate instructions for shaking, measuring the prescribed quantity, refrigeration and disposal. Caregivers should use a suitable calibrated oral measuring device and clarify any uncertainty about the bottle's preparation status with the pharmacy.
This product-specific preparation information differs from the four standard suspension concentration families. Readers interested in ordinary liquid packages and concentrations can use the standard Augmentin suspension guide; the present page covers only ES-600.
| ES-600 final bottle size | FDA-labeled water amount | Finished product concentration |
|---|---|---|
| 75 mL | 70 mL | 600 mg/42.9 mg per 5 mL |
| 125 mL | 110 mL | 600 mg/42.9 mg per 5 mL |
| 200 mL | 180 mL | 600 mg/42.9 mg per 5 mL |
The FDA labeling distinguishes storage of unreconstituted ES-600 powder from storage of the finished suspension. The dry powder should be stored at or below 25°C (77°F). After reconstitution, the suspension must be kept in its original container under refrigeration and any unused liquid discarded after 10 days. This ten-day limit relates to prepared-product stability and is not a general recommendation for treatment duration.
The label directs users to shake the prepared suspension well before each administration. A slight color change during refrigerated storage may be normal, but unexpected changes, uncertain preparation dates or interruptions in proper storage should be discussed with the dispensing pharmacist before the medicine is administered.
ES-600 contains aspartame, which is a source of phenylalanine. The FDA specifies 7 mg of phenylalanine in each 5 mL of prepared branded ES-600 suspension. This is relevant to patients with phenylketonuria, or PKU, and makes exact formulation verification important. A clinician and pharmacist should review the product and the patient's circumstances when phenylalanine exposure is a concern.
The FDA also describes limited flavoring options for ES-600 when added according to its professional preparation instructions. Because stability has not been established for every flavoring agent, caregivers should not independently add ingredients to a prepared prescription suspension.
Prepared ES-600 should not be saved for a later illness or used after its labeled discard period. A new infection requires a fresh clinical assessment, and antibiotics should not be reused without an appropriate prescription.
| Product characteristic | FDA-labeled information | Verification consideration |
|---|---|---|
| Dry powder storage | At or below 25°C (77°F) | Follow original package instructions before preparation. |
| Prepared suspension storage | Refrigerate in the original container | Confirm pharmacy storage instructions and preparation date. |
| Post-reconstitution period | Discard unused suspension after 10 days | Not equivalent to a standard treatment-duration recommendation. |
| Before administration | Shake well | Use an appropriate calibrated oral measuring device. |
| Phenylalanine | 7 mg per 5 mL of branded ES-600 | Relevant to professional review for patients with PKU. |
Section 2.8 of the July 2026 FDA prescribing information explicitly states that Augmentin ES-600 is not substitutable with other Augmentin formulations or Augmentin XR extended-release tablets. This is a product-specific restriction rather than a generic warning that all amoxicillin/clavulanate products differ.
Standard Augmentin oral suspensions contain 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg or 400 mg/57 mg per 5 mL. They have 4:1 or approximately 7:1 component ratios. ES-600 has an approximately 14:1 ratio, so exchanging liquids solely on the basis of an amoxicillin quantity can change the clavulanate proportion.
The FDA also states that ES-600 must not be used as a substitute for conventional Augmentin 500 mg/125 mg or 875 mg/125 mg tablets. Augmentin XR adds a separate extended-release design, which further distinguishes it from ES-600. Similar brand names or shared active ingredients do not override the explicit substitution limitations.
The applicable FDA guidance for changing among certain conventional tablets, chewables and standard suspensions does not extend automatically to ES-600. A pharmacy product menu that places these products under one ingredient heading should not be interpreted as permission to select a different concentration or dosage form.
Any problem obtaining the exact prescribed ES-600 package must be handled by the dispensing pharmacist and, when necessary, the prescriber. Families should not estimate replacement volumes, combine medicines or use leftover Augmentin products as substitutes.
A focused side-by-side discussion belongs on Augmentin ES-600 vs regular Augmentin. Related dosage-form guides include standard Augmentin tablets, chewable tablets and Augmentin XR.
Augmentin ES-600 is a named branded formulation rather than a generic description for every high-concentration amoxicillin/clavulanate suspension. Its exact active-ingredient concentration, FDA indications, labeling and approved product identity should be established before interpreting any pharmacy listing as a match.
Generic products can be approved through Abbreviated New Drug Applications when they meet the applicable FDA requirements for a particular reference product. An authorized generic is a distinct regulatory category marketed without the brand name under an approved brand NDA. Neither the presence of nonproprietary ingredient names nor a similar concentration establishes that a specific product is an approved, therapeutically equivalent alternative to ES-600.
The FDA Orange Book and published labeling provide different verification layers. Approval records can help identify the relevant application and reference relationship, while a product label may show the listed name, dosage form, strength, labeler and package NDC. The approval status and current commercial marketing of a particular ES-600-related product must be verified separately.
Manufacturer, distributor and labeler identities should not be treated as interchangeable. A repackaged product can have a different NDC from the original branded presentation, and an online catalog can contain historical records. The actual pharmacy must identify what it proposes to dispense.
The FDA-approved Augmentin products guide addresses approval records and therapeutic-equivalence evaluations, while the generic manufacturers directory covers company-specific information. This page does not claim that a generic ES-600 product is currently marketed or stocked.
Augmentin ES-600 is a prescription-only antibacterial medicine in the United States. A legitimate pharmacy must process a valid prescription and confirm the intended product before dispensing. The central product check is the full branded formulation identity: Augmentin ES-600, powder for oral suspension, 600 mg amoxicillin and 42.9 mg clavulanic acid per 5 mL after reconstitution.
The pharmacy should verify the actual product, approved package identity, prepared volume and NDC when applicable. It must also establish whether the liquid has been reconstituted and provide appropriate directions for administration, storage and the discard date. A pharmacy listing that mentions Augmentin liquid without the full strength pair is insufficient to identify ES-600.
Because ES-600 is subject to explicit non-substitution restrictions, the pharmacy should not assume that ordinary Augmentin liquid, chewable tablets or XR can replace it. If the exact prescribed product is unavailable, the dispensing professional must determine the next appropriate step and seek prescriber involvement when necessary.
Parents and caregivers should clarify unexpected changes in concentration, product name or preparation status before giving the medicine. The pharmacy can also confirm the supplied measuring device and any clinically relevant inactive ingredients, including phenylalanine exposure for patients with PKU.
A published NDC, FDA approval listing or website product card is not evidence of real-time inventory, lawful prescription processing or guaranteed clinical approval. These matters require confirmation through the actual licensed dispensing service.
General prescription-based purchasing information belongs in the U.S. Augmentin buying guide. Pharmacy verification and access questions are addressed in the Augmentin online pharmacy guide.
| Pharmacy verification point | Information to confirm | Why it matters |
|---|---|---|
| Prescription | Valid prescription identifying Augmentin ES-600 | A product search result does not authorize dispensing. |
| Active ingredients | Amoxicillin and clavulanate potassium | Distinguishes ES-600 from plain amoxicillin liquid. |
| Strength | 600 mg/42.9 mg per 5 mL after reconstitution | Separates ES-600 from standard Augmentin suspensions. |
| Dosage form | Powder for oral suspension | Requires correct preparation and concentration verification. |
| Bottle and NDC | Actual 75 mL, 125 mL or 200 mL labeled presentation, where applicable | Helps reconcile the package with approved labeling. |
| Preparation status | Correct reconstitution and final prepared volume | Ensures that the prescribed concentration applies. |
| Handling | Refrigeration, shaking and the post-reconstitution discard date | Important for safe use of the prepared liquid. |
| Substitution restrictions | ES-600-specific FDA labeling and prescription requirements | Prevents inappropriate replacement with other Augmentin formulations. |
Augmentin ES-600 contains amoxicillin, a penicillin-class antibacterial, and is subject to FDA contraindications involving serious hypersensitivity reactions to the product or other beta-lactam antibacterial drugs. Previous Augmentin-associated cholestatic jaundice or hepatic dysfunction is also a contraindication. A patient's medical and allergy history must be evaluated by the prescribing professional.
The labeling describes potential adverse reactions including diarrhea, vomiting, rash and other gastrointestinal or skin-related effects. Serious risks include anaphylaxis, severe cutaneous adverse reactions, liver injury, drug-induced enterocolitis syndrome and Clostridioides difficile-associated diarrhea. Sudden breathing difficulty or swelling of the face or throat requires emergency medical attention; other significant symptoms require prompt clinical review.
ES-600 contains aspartame, supplying 7 mg of phenylalanine per 5 mL of prepared suspension. This is a specific concern for patients with phenylketonuria. The product also has medication-interaction and patient-specific considerations, including interactions with probenecid, oral anticoagulants and allopurinol, and special restrictions in severe renal impairment.
Antibiotic treatment should be reserved for an appropriate bacterial indication. ES-600 does not treat viral infections such as influenza or the common cold. Families should not share antibiotics, use leftover suspension for a later illness or change concentration or administration instructions independently.
For broader information about beta-lactam hypersensitivity, see the penicillin allergy guide. This product-identification page does not provide individualized pediatric treatment selection or dosing advice.
FDA approval and published bottle identifiers do not guarantee that branded Augmentin ES-600 is available at a particular U.S. pharmacy. A pharmacy may display the product in its catalog without having the exact package available for dispensing. Current commercial supply must be verified for the actual prescription.
Out-of-pocket cost may depend on the branded product, dispensing quantity, pharmacy, insurance benefits and applicable discounts. The 75 mL, 125 mL and 200 mL labeled packages represent different total volumes even though their prepared concentrations are identical. A price for standard Augmentin suspension should not be interpreted as a price for ES-600.
If the intended formulation is unavailable, the pharmacy must address the issue through appropriate professional channels rather than treating an ordinary Augmentin concentration as interchangeable. The specific product and prescription should be established before any price or availability comparison.
Broader brand costs belong in the Augmentin price guide, while liquid-product cost questions can be explored in the Augmentin suspension pricing guide. This page does not provide unverified offers, guaranteed stock, insurance promises or delivery claims.
Augmentin ES-600 is a prescription antibacterial powder for oral suspension containing amoxicillin and clavulanate potassium. After reconstitution, each 5 mL contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid. It is a separately labeled pediatric formulation.
It identifies the amounts of the two active components in 5 mL of correctly prepared suspension: 600 mg of amoxicillin and 42.9 mg of clavulanic acid, supplied as clavulanate potassium. The numbers describe the finished liquid concentration, not the total amount in the bottle.
Augmentin ES-600 has an approximately 14:1 amoxicillin-to-clavulanic-acid ratio. This differs from the 4:1 and approximately 7:1 ratios used in standard Augmentin oral suspensions. The ratio describes formulation composition, not comparative clinical effectiveness.
The July 2026 FDA consolidated prescribing information identifies ES-600 for specified cases of acute bacterial sinusitis and recurrent or persistent acute otitis media in its labeled pediatric population. The indications have organism, susceptibility and clinical restrictions, so the medicine is not appropriate for every sinus or ear infection.
The July 2026 FDA labeling specifies pediatric patients aged 3 months to 12 years weighing 8 kg to 40 kg. The product is not automatically appropriate for every child within those limits. Clinical assessment and a valid prescription are required.
No. ES-600 contains 600 mg/42.9 mg per 5 mL and has an approximately 14:1 component ratio. Standard Augmentin suspensions use four other labeled concentration pairs with different component ratios. The FDA states that ES-600 is not substitutable with other Augmentin formulations.
No automatic substitution is permitted. The standard 400/57 mg suspension and ES-600 have different active-component concentrations and ratios. The FDA explicitly identifies ES-600 as not substitutable with other Augmentin formulations. Any treatment change requires professional assessment.
No. The FDA specifically states that ES-600 should not be used as a substitute for conventional Augmentin 500/125 mg or 875/125 mg tablets. ES-600 has different strength proportions, dosage-form characteristics and labeled population requirements.
No. ES-600 is a pediatric oral suspension with 600 mg/42.9 mg per 5 mL after reconstitution. Augmentin XR is an extended-release tablet with 1,000 mg/62.5 mg per tablet. The FDA identifies them as distinct, non-interchangeable formulations.
The July 2026 FDA prescribing information lists 75 mL, 125 mL and 200 mL branded ES-600 bottle configurations. These are labeled final suspension volumes, not a guarantee that every package is currently stocked by a particular pharmacy.
The FDA label lists 81964-003-51 for the 75 mL bottle, 81964-003-69 for the 125 mL bottle and 81964-003-54 for the 200 mL bottle. NDCs help identify labeled packages but do not independently establish current inventory or clinical suitability.
ES-600 is supplied as a powder for oral suspension that requires reconstitution. The FDA provides bottle-specific preparation instructions for the dispensing process. Families should have the pharmacy confirm that the intended product has been prepared correctly rather than estimating water quantities independently.
Yes, after reconstitution. The FDA directs that the prepared suspension be stored in its original container under refrigeration. The unreconstituted dry powder has different storage requirements. Patients should follow the actual dispensing label.
The FDA labeling requires unused reconstituted ES-600 suspension to be discarded after 10 days. This is a product stability limit following preparation, not a universal instruction about treatment duration.
Yes. The branded ES-600 formulation contains aspartame, a source of phenylalanine. The FDA label identifies 7 mg phenylalanine per 5 mL of prepared suspension. This is important for patients with phenylketonuria and requires professional review.
The existence of an amoxicillin/clavulanate product listing does not establish an approved or currently marketed generic equivalent to ES-600. Any particular product's FDA application, dosage form, strength, therapeutic-equivalence status and current marketing must be verified independently.
No. ES-600 is a prescription-only antibacterial medicine in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. Online listings do not establish prescription-free access or guaranteed prescription approval.
Check the actual dispensed product name, the complete 600 mg/42.9 mg per 5 mL concentration, prepared bottle quantity and prescription directions. Ask the pharmacist to confirm the package identifier, reconstitution status, storage requirements and discard date.
No. FDA approval, prescribing information and NDC listings establish product and regulatory information but do not provide real-time pharmacy inventory. The pharmacy must confirm whether the exact prescribed product and quantity can be dispensed.
ES-600 contains amoxicillin, a penicillin-class antibacterial. FDA labeling contraindicates use in patients with a history of serious hypersensitivity reactions to the product or other beta-lactam antibacterial drugs. An allergy history requires professional evaluation before prescribing.